Cardiovascular and Metabolic

Driven by Our Promise

CSL is committed to developing novel therapies that save and improve the lives of patients with life-threatening diseases. As part of this commitment, we have established a Therapeutic Area that focuses on the #1 cause of death worldwide: Cardiovascular and Metabolic (CV&M) disease.

Our goal is to address areas of high, unmet medical need, and we strive to develop new approaches that will greatly improve how we treat these significant global health concerns.

We have assembled a global team of CV&M experts who have capabilities spanning across all phases of development. Our scientific expertise encompasses three research platforms: plasma-derived therapeutics, recombinant technologies and gene and cell therapies, each offering a unique approach to solving this global health crisis.

Congress Materials

AHA 2020 | 13–17 November 2020 | View Materials
ESC 2021 | 15-17 May 2021 | View Materials

Meet Us at an Event

European Society of Cardiology (ESC)	26–29 August 2022	Barcelona, Spain	Details
American Heart Association (AHA) Scientific Sessions	5–7 November 2022	Chicago, IL USA	Details

Cardiovascular and Metabolic Resources

Video: The Importance of ApoA-I in Cholesterol Efflux and Atherosclerosis

As a key functional component of high-density lipoprotein, apolipoprotein A1 mediates cholesterol efflux from atherosclerotic plaques. This video provides an overview of the important role apolipoprotein A1 plays in cholesterol efflux and plaque stabilization.

Podcast: Cholesterol Efflux Capacity: What is it and What Does it Mean for Cardiovascular Outcomes?

Listen to Dr Anand Rohatgi describe the process of cholesterol efflux and the data that demonstrate the importance of cholesterol efflux capacity in determining cardiovascular outcomes.
References

Download Podcast

CMD-CRP-0001
MED-ALL-112-00433
August 2021